FIELD: medical biotechnology.
SUBSTANCE: invention relates to medical biotechnology, namely to the use of options of natriuretic peptide of type C (CNP) for the treatment of osteoarthritis for the relief of one or several osteoarthritis symptoms and for the treatment of disorders having osteoarthritis component.
EFFECT: invention allows for long-term relief for patients with osteoarthritis.
22 cl, 10 tbl, 27 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CNP PRODRUGS | 2016 |
|
RU2824988C1 |
| AMATOXIN ANTIBODY-DRUG CONJUGATES AND USE THEREOF | 2020 |
|
RU2826004C2 |
| CONTROLLED RELEASE COMBINATION THERAPY WITH CNP AGONISTS | 2017 |
|
RU2768747C2 |
| ANTIBODIES TO TAU AND THEIR USE | 2018 |
|
RU2787779C2 |
| RECOMBINANT MODIFIED FIBROBLAST GROWTH FACTORS AND THEIR THERAPEUTIC USE | 2018 |
|
RU2811435C2 |
| ADAMTS-BINDING IMMUNOGLOBULINS | 2018 |
|
RU2781182C2 |
| ANTIBODIES DIRECTED AGAINST THE INTERLEUKIN 36 (IL-36R) RECEPTOR | 2016 |
|
RU2745898C2 |
| ANTI-C10orf54 ANTIBODIES AND APPLICATIONS THEREOF | 2015 |
|
RU2819627C1 |
| COMBINATION THERAPY BASED ON T-CELL-ACTIVATING BISPECIFIC ANTIGEN-BINDING MOLECULES AGAINST CD3 AND FOLATE RECEPTOR 1 (FOLR1) AND ANTAGONISTS BINDING TO PD-1 AXIS | 2015 |
|
RU2753902C2 |
| IMMUNOGLOBULINS BINDING AGGRECAN | 2018 |
|
RU2771818C2 |
